Global Sepsis Diagnostics Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2020 –2029 |
 Marktgröße (Basisjahr) | |
 Marktgröße (Prognosejahr) | USD 16.53 Billion |
 CAGR |
% |
| Wichtige Marktteilnehmer |
|
Global Sepsis Diagnostics Market, By Techniques (Immunoassay, Molecular Diagnostic, Microbiology & Flow Cytometry), Test Type (Laboratory Testing & Point of Care Testing) Industry Trends and Forecast to 2029.
Global Market Analysis and Insights : Global Sepsis Diagnostics Market
Sepsis is a potentially life-threatening condition that occurs when the body's response to an infection damages its own tissues. When the infection-fighting processes turn on the body, they cause organs to function poorly and abnormally. Sepsis may progress to septic shock. This is a dramatic drop in blood pressure that can lead to severe organ problems and death. To be diagnosed with sepsis, it is must to confirm the infection with signs such as change in mental status, systolic blood pressure, respiratory rate. Most often, sepsis occurs in people who are hospitalized or who have recently been hospitalized. People in an intensive care unit are more likely to develop infections that can then lead to sepsis. For the diagnosis of sepsis along with blood test other lab test needs to be done. Blood samples are used to test for evidence of infection, clotting problems, abnormal liver or kidney function, impaired oxygen availability, electrolyte imbalances. People who have sepsis require close monitoring and treatment in a hospital intensive care unit. Lifesaving measures may be needed to stabilize breathing and heart function.
Data Bridge Market Research analyses that the market is growing with a CAGR of 8.0% in the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2019-2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
By Techniques (Immunoassay, Molecular Diagnostic, Microbiology & Flow Cytometry), Test Type (Laboratory Testing & Point of Care Testing) |
|
Countries Covered |
U.S. and Rest of North America in North America, Germany, France, U.K. and Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Brazil and Rest of South America as part of South America. South Africa, Saudi Arabia and Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA). |
|
Market Players Covered |
The major companies which are dealing in the market are Trinity Biotech (Ireland), Meridian Bioscience (U.S.), Omega Diagnostics Group PLC. (U.K.), Xcyton Diagnostics Limited (india), Diasorin S.p.A (Italy), Seegene Inc. (South Korea), EKF Diagnostics Holdings plc (U.K.), Axis-Shield Diagnostics Ltd. (U.K.), Immunexpress Inc. (U.S.), Luminex Corporation (U.S.), bioMérieux SA (France), BD (U.S.), Thermo Fisher Scientific Inc.(U.S.), Abbott (U.S), Roche Diagnostics (U.S), Cepheid (U.S.), Beckman Coulter, Inc. (U.S.), T2 Biosystems, Inc. (U.S.), Bruker (U.S.) and Ortho Clinical Diagnostics (U.S.). |
Sepsis Diagnostics Market Dynamics
Drivers
- Rising incidence of hospital-acquired infections
With the rapid increase in HAIs worldwide, there is an increase in the demand for proper sepsis diagnostic products will increase in upcoming years. Therefore, rising incidences of hospital-acquired infections are expected to act as a driver for the growth of the sepsis diagnostics market.
- Rising healthcare expenditure
Another significant factor influencing the growth rate of sepsis diagnostics market is the rising healthcare expenditure which helps in improving its infrastructure.
- Growing prevalence of sepsis
Growing prevalence of sepsis in various regions worldwide and various infections associated with it are expected to act as drivers for the growth of the sepsis diagnostics market
Furthermore, advancement in medical technology, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the sepsis diagnostics market.
Opportunities
- Evolution of novel biomarkers for sepsis diagnosis
Sepsis is one of the leading causes of mortality and morbidity, even with the current availability of extended-spectrum antibiotics and advanced medical care. Biomarkers offer a tool in facilitating early diagnosis, in identifying patient populations at high risk of complications, and in monitoring the progression of the disease, which are critical assessments for appropriate therapy and improvement in patient outcomes.
Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the sepsis diagnostics market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate sepsis diagnostics market in future.
Restraints/Challenges
However, high cost of diagnosis and lack of appropriate testing for sepsis will impede the growth rate of sepsis diagnostics market. Additionally, lack of awareness about sepsis will further challenge the market in the forecast period mentioned above.
This sepsis diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on sepsis diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Post COVID-19 Impact on Sepsis Diagnostics Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in sepsis medication adherence during the pandemic.
Recent Development
- In May 2020, Beckman Coulter announced the availability of its DxH 690T hematology analyzer in the U.S. which is used as the early sepsis indicator. This announcement has helped company to increase its global presence and growth in the revenue as well.
Global Sepsis Diagnostics Market Scope
The Global sepsis diagnostics market is segmented into techniques and test type. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Techniques
- Immunoassay
- Molecular Diagnostic
- Microbiology
- Flow Cytometry
On the basis of techniques, the global sepsis diagnostics market is segmented into microbiology, molecular diagnostic, immunoassay, and flow cytometry.
Test Type
- Laboratory Testing
- Point of Care Testing
On the basis of test type, the global sepsis diagnostics market is segmented into laboratory testing and point of care testing.
Sepsis Diagnostics Market Regional Analysis/Insights
The sepsis diagnostics market is analysed and market size insights and trends are provided by country, techniques and test type as referenced above.
The countries covered in the sepsis diagnostics market report are U.S., rest of North America, Germany, U.K., France, rest of Europe, China, India, Japan, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Rest of South America, Saudi Arabia, South Africa, rest of Middle East and Africa.
North America dominates the sepsis diagnostics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region combined with rising number of the adult population getting diagnosed positive for sepsis, each year in the region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increasing healthcare expenditure by the government of developing nations and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Sepsis Diagnostics Market Share Analysis
The sepsis diagnostics market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on sepsis diagnostics market.
Some of the major players operating in the sepsis diagnostics market are Trinity Biotech (Ireland), Meridian Bioscience, Omega Diagnostics Group PLC., Xcyton Diagnostics Limited, Diasorin S.p.A, Seegene Inc., EKF Diagnostics Holdings plc., Axis-Shield Diagnostics Ltd., Immunexpress Inc., Luminex Corporation, bioMérieux SA, BD, Thermo Fisher Scientific Inc. Abbott, Roche Diagnostics, Cepheid, Beckman Coulter, Inc., T2 Biosystems, Inc., and Bruker Ortho Clinical Diagnostics among others.
Research Methodology: Global Sepsis Diagnostics Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In adition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL SEPSIS DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TECHNIQUES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TECHNIQUES COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
5.1.2 RISE IN HEALTHCARE EXPENDITURE
5.1.3 GROW IN PREVALENCE OF SEPSIS
5.1.4 RISE IN TECHNOLOGICAL ADVANCEMENTS OF SEPSIS DIAGNOSTIC DEVICES
5.2 RESTRAINTS
5.2.1 HIGH COST OF DIAGNOSIS
5.2.2 LACK OF APPROPRIATE TESTING FOR SEPSIS
5.3 OPPORTUNITIES
5.3.1 DEVELOPMENT OF RAPID DIAGNOSTIC/POINT OF CARE (POC) TECHNIQUES FOR EARLY SEPSIS DIAGNOSIS
5.3.2 EVOLUTION OF NOVEL BIOMARKERS FOR SEPSIS DIAGNOSIS
5.4 CHALLENGES
5.4.1 LACK OF AWARENESS ABOUT SEPSIS
5.4.2 SHORTAGE OF SKILLED HEALTHCARE PROFESSIONALS
6 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES
6.1 OVERVIEW
6.2 IMMUNOASSAY
6.2.1 PROCALCITONIN (PCT)
6.2.2 INTERLEUKIN-6 (IL-6)
6.2.3 C-REACTIVE PROTEIN (CRP)
6.2.4 PENTRAXIN-3 (PTX3)
6.2.5 CALPROTECTIN
6.2.6 OTHERS
6.3 MOLECULAR DIAGNOSTIC
6.4 MICROBIOLOGY
6.5 FLOW CYTOMETRY
7 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE
7.1 OVERVIEW
7.2 LABORATORY TESTING
7.3 POINT OF CARE TESTING
8 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 OVERVIEW
8.2.2 U.S.
8.2.3 REST OF NORTH AMERICA
8.3 EUROPE
8.3.1 OVERVIEW
8.3.2 GERMANY
8.3.3 U.K.
8.3.4 FRANCE
8.3.5 REST OF EUROPE
8.4 ASIA-PACIFIC
8.4.1 OVERVIEW
8.4.2 CHINA
8.4.3 INDIA
8.4.4 JAPAN
8.4.5 SOUTH KOREA
8.4.6 AUSTRALIA
8.4.7 SINGAPORE
8.4.8 THAILAND
8.4.9 MALAYSIA
8.4.10 INDONESIA
8.4.11 PHILIPPINES
8.4.12 REST OF ASIA-PACIFIC
8.5 SOUTH AMERICA
8.5.1 OVERVIEW
8.5.2 BRAZIL
8.5.3 REST OF SOUTH AMERICA
8.6 MIDDLE EAST AND AFRICA
8.6.1 OVERVIEW
8.6.2 SOUTH AFRICA
8.6.3 SAUDI ARABIA
8.6.4 REST OF MIDDLE EAST AND AFRICA
9 GLOBAL SEPSIS DIAGNOSTICS MARKET: COMPANY LANDSCAPE
9.1 COMPANY SHARE ANALYSIS: GLOBAL
9.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
9.3 COMPANY SHARE ANALYSIS: EUROPE
9.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
10 COMPANY PROFILE
10.1 ROCHE DIAGNOSTICS
10.1.1 COMPANY SNAPSHOT
10.1.2 REVENUE ANALYSIS
10.1.3 COMPANY SHARE ANALYSIS
10.1.4 PRODUCT PORTFOLIO
10.1.5 RECENT DEVELOPMENT
10.2 ABBOTT.
10.2.1 COMPANY SNAPSHOT
10.2.2 REVENUE ANALYSIS
10.2.3 COMPANY SHARE ANALYSIS
10.2.4 PRODUCT PORTFOLIO
10.2.5 RECENT DEVELOPMENT
10.2.5.1 PRODUCT LAUNCH
10.3 BIOMERIEUX SA
10.3.1 COMPANY SNAPSHOT
10.3.2 REVENUE ANALYSIS
10.3.3 COMPANY SHARE ANALYSIS
10.3.4 PRODUCT PORTFOLIO
10.3.5 RECENT DEVELOPMENT
10.3.5.1 PRODUCT LAUNCH
10.4 THERMO FISHER SCINETIFIC INC.
10.4.1 COMPANY SNAPSHOT
10.4.2 REVENUE ANALYSIS
10.4.3 COMPANY SHARE ANALYSIS
10.4.4 PRODUCT PORTFOLIO
10.4.5 RECENT DEVELOPMENT
10.4.5.1 ACQUISITION
10.5 BD
10.5.1 COMPANY SNAPSHOT
10.5.2 REVENUS ANALYSIS
10.5.3 COMPANY SHARE ANALYSIS
10.5.4 PRODUCT PORTFOLIO
10.5.5 RECENT DEVELOPMENT
10.6 SEEGENE INC.
10.6.1 COMPANY SNAPSHOT
10.6.2 REVENUE ANALYSIS
10.6.3 PRODUCT PORTFOLIO
10.6.4 RECENT DEVELOPMENT
10.7 AXIS-SHIELD DIAGNOSTICS LTD.
10.7.1 COMPANY SNAPSHOT
10.7.2 PRODUCT PORTFOLIO
10.7.3 RECENT DEVELOPMENTS
10.8 BECKMAN COULTER, INC.
10.8.1 COMPANY SNAPSHOT
10.8.2 PRODUCT PORTFOLIO
10.8.3 RECENT DEVELOPMENTS
10.9 BRUKER
10.9.1 COMPANY SNAPSHOT
10.9.2 REVENUS ANALYSIS
10.9.3 PRODUCT PORTFOLIO
10.9.4 RECENT DEVELOPMENTS
10.1 CEPHEID
10.10.1 COMPANY SNAPSHOT
10.10.2 REVENUE ANALYSIS
10.10.3 PRODUCT PORTFOLIO
10.10.4 RECENT DEVELOPMENT
10.10.4.1 PROGRAM LAUNCH
10.11 DIASORIN S.P.A.
10.11.1 COMPANY SNAPSHOT
10.11.2 REVENUE ANALYSIS
10.11.3 PRODUCT PORTFOLIO
10.11.4 RECENT DEVELOPMENT
10.11.4.1 ACQUISITION
10.12 EKF DIAGNOSTICS HOLDINGS PLC
10.12.1 COMPANY SNAPSHOT
10.12.2 REVENUE ANALYSIS
10.12.3 PRODUCT PORTFOLIO
10.12.4 RECENT DEVELOPMENT
10.12.4.1 ACQUISITION
10.13 IMMUNEXPRESS INC.
10.13.1 COMPANY SNAPSHOT
10.13.2 PRODUCT PORTFOLIO
10.13.3 RECENT DEVELOPMENT
10.13.3.1 PRODUCT LAUNCH
10.14 LUMINEX CORPORATION.
10.14.1 COMPANY SNAPSHOT
10.14.2 PRODUCT PORTFOLIO
10.14.3 RECENT DEVELOPMENT
10.14.3.1 ACQUISITION
10.15 MERIDIAN BIOSCIENCE
10.15.1 COMPANY SNAPSHOT
10.15.2 REVENUS ANALYSIS
10.15.3 PRODUCT PORTFOLIO
10.15.4 RECENT DEVELOPMENTS
10.16 OMEGA DIAGNOSTICS GROUP PLC
10.16.1 COMPANY SNAPSHOT
10.16.2 REVENUE ANALYSIS
10.16.3 PRODUCT PORTFOLIO
10.16.4 RECENT DEVELOPMENT
10.17 ORTHO CLINICAL DIAGNOSTICS.
10.17.1 COMPANY SNAPSHOT
10.17.2 REVENUE ANALYSIS
10.17.3 PRODUCT PORTFOLIO
10.17.4 RECENT DEVELOPMENT
10.17.4.1 PRODUCT LAUNCH
10.18 T2 BIOSYSTEM, INC.
10.18.1 COMPANY SNAPSHOT
10.18.2 PRODUCT PORTFOLIO
10.18.3 RECENT DEVELOPMENT
10.18.3.1 PRODUCT LAUNCH
10.19 TRINITY BIOTECH
10.19.1 COMPANY SNAPSHOT
10.19.2 REVENUE ANALYSIS
10.19.3 PRODUCT PORTFOLIO
10.19.4 RECENT DEVELOPMENT
10.2 XCTON DAGNOSTICS LIMITED
10.20.1 COMPANY SNAPSHOT
10.20.2 PRODUCT PORTFOLIO
10.20.3 RECENT DEVELOPMENT
11 QUESTIONNAIRE
12 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 2 GLOBAL IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 3 GLOBAL IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 4 GLOBAL IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 5 GLOBAL MOLECULAR DIAGNOSTICS IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 6 GLOBAL MICROBIOLOGY IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 7 GLOBAL FLOW CYTOMETRY IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 8 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 9 GLOBAL LABORATORY TESTING IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 10 GLOBAL POINT OF CARE TESTING IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 11 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)
TABLE 12 NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2019-2029 (USD MILLION)
TABLE 13 NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 14 NORTH AMERICA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 15 NORTH AMERICA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 16 NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 17 U.S. SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 18 U.S. IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 19 U.S. IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 20 U.S. SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 21 REST OF NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 22 EUROPE SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2019-2029 (USD MILLION)
TABLE 23 EUROPE SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 24 EUROPE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 25 EUROPE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 26 EUROPE SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 27 GERMANY SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 28 GERMANY IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 29 GERMANY IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 30 GERMANY SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 31 U.K. SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 32 U.K. IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 33 U.K. IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 34 U.K. SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 35 FRANCE SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 36 FRANCE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 37 FRANCE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 38 FRANCE SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 39 REST OF EUROPE SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2019-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 44 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 45 CHINA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 46 CHINA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 47 CHINA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 48 CHINA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 49 INDIA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 50 INDIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 51 INDIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 52 INDIA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 53 JAPAN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 54 JAPAN IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 55 JAPAN IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 56 JAPAN SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 57 SOUTH KOREA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 58 SOUTH KOREA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 59 SOUTH KOREA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 60 SOUTH KOREA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 61 AUSTRALIA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 62 AUSTRALIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 63 AUSTRALIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 64 AUSTRALIA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 65 SINGAPORE SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 66 SINGAPORE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 67 SINGAPORE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 68 SINGAPORE SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 69 THAILAND SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 70 THAILAND IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 71 THAILAND IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 72 THAILAND SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 73 MALAYSIA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 74 MALAYSIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 75 MALAYSIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 76 MALAYSIA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 77 INDONESIA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 78 INDONESIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 79 INDONESIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 80 INDONESIA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 81 PHILIPPINES SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 82 PHILIPPINES IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 83 PHILIPPINES IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 84 PHILIPPINES SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 85 REST OF ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 86 SOUTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2019-2029 (USD MILLION)
TABLE 87 SOUTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 88 SOUTH AMERICA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 89 SOUTH AMERICA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 90 SOUTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 91 BRAZIL SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 92 BRAZIL IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 93 BRAZIL IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 94 BRAZIL SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 95 REST OF SOUTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 96 MIDDLE EAST AND AFRICA SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2019-2029 (USD MILLION)
TABLE 97 MIDDLE EAST AND AFRICA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 98 MIDDLE EAST AND AFRICA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 99 MIDDLE EAST AND AFRICA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 100 MIDDLE EAST AND AFRICA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 101 SOUTH AFRICA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 102 SOUTH AFRICA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 103 SOUTH AFRICA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 104 SOUTH AFRICA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 105 SAUDI ARABIA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 106 SAUDI ARABIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
TABLE 107 SAUDI ARABIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)
TABLE 108 SAUDI ARABIA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)
TABLE 109 REST OF MIDDLE EAST AND AFRICA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)
Abbildungsverzeichnis
FIGURE 1 GLOBAL SEPSIS DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 GLOBAL SEPSIS DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL SEPSIS DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL SEPSIS DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL SEPSIS DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL SEPSIS DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL SEPSIS DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL SEPSIS DIAGNOSTICS MARKET: MARKET TECHNIQUES COVERAGE GRID
FIGURE 9 GLOBAL SEPSIS DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL SEPSIS DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE GROWING PREVALENCE OF SEPSIS IS EXPECTED TO DRIVE THE GLOBAL SEPSIS DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 TECHNIQUES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL SEPSIS DIAGNOSTICS MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA TO DOMINATE AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE GLOBAL SEPSIS DIAGNOSTICS MARKET FROM 2022 TO 2029
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR SEPSIS DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 DRIVERS, RESTRAINT, OPPORTUNITIES, AND CHALLENGES FOR THE GLOBAL SEPSIS DIAGNOSTICS MARKET
FIGURE 16 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, 2021
FIGURE 17 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, 2022-2029 (USD MILLION)
FIGURE 18 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, CAGR (2022-2029)
FIGURE 19 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, LIFELINE CURVE
FIGURE 20 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, 2021
FIGURE 21 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, 2022-2029 (USD MILLION)
FIGURE 22 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2022-2029)
FIGURE 23 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL SEPSIS DIAGNOSTICS MARKET: SNAPSHOT (2021)
FIGURE 25 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY REGION (2021)
FIGURE 26 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY REGION (2022 & 2029)
FIGURE 27 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY REGION (2021 & 2029)
FIGURE 28 GLOBAL SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES (2022-2029)
FIGURE 29 NORTH AMERICA SEPSIS DIAGNOSTICS MARKET: SNAPSHOT (2021)
FIGURE 30 NORTH AMERICA SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021)
FIGURE 31 NORTH AMERICA SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 32 NORTH AMERICA SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 33 NORTH AMERICA SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES (2022-2029)
FIGURE 34 EUROPE SEPSIS DIAGNOSTICS MARKET: SNAPSHOT (2021)
FIGURE 35 EUROPE SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021)
FIGURE 36 EUROPE SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 37 EUROPE SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 38 EUROPE SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES (2022-2029)
FIGURE 39 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET: SNAPSHOT (2021)
FIGURE 40 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021)
FIGURE 41 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 42 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 43 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES (2022-2029)
FIGURE 44 SOUTH AMERICA SEPSIS DIAGNOSTICS MARKET: SNAPSHOT (2021)
FIGURE 45 SOUTH AMERICA SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021)
FIGURE 46 SOUTH AMERICA SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 SOUTH AMERICA SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 SOUTH AMERICA SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES (2022-2029)
FIGURE 49 MIDDLE EAST AND AFRICA SEPSIS DIAGNOSTICS MARKET: SNAPSHOT (2021)
FIGURE 50 MIDDLE EAST AND AFRICA SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021)
FIGURE 51 MIDDLE EAST AND AFRICA SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 52 MIDDLE EAST AND AFRICA SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 53 MIDDLE EAST AND AFRICA SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES (2022-2029)
FIGURE 54 GLOBAL SEPSIS DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)
FIGURE 55 NORTH AMERICA SEPSIS DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)
FIGURE 56 EUROPE SEPSIS DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)
FIGURE 57 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
